SCHEMBL230603

SCHEMBL230603

CSc1ccc(C(O)c2cccc(F)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
ESR1 P03372 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
BRD4 O60885 2/20 0.40
ALOX5 P09917 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
EPHX1 P07099 1/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A2 P23975 1/20 0.37
IGFBP3 P17936 1/20 0.36
CREBBP Q92793 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230519 0.82 CES2 (0.49) CES2CES1BRD4HDAC4HDAC7
SCHEMBL227352 0.82 CES2 (0.55) CES2CES1BRD4HDAC4HDAC7
SCHEMBL28788047 0.81 BRD4 (0.49) CES2CES1BRD4HDAC4HDAC7
SCHEMBL19619722 0.80 SLC6A4 (0.43) ALDH1A1ESR1HDAC4HDAC7HDAC5
SCHEMBL5723313 0.80 PTGS1 (0.36) ALDH1A1ESR1CES2CES1BRD4
SCHEMBL230487 0.80 IDO1 (0.52) CES2CES1BRD4HDAC4HDAC7
SCHEMBL5109088 0.80 KDM4E (0.49) ALDH1A1SLC6A4
SCHEMBL6182478 0.80 SLC6A4 (0.50) ALDH1A1ALOX5SLC6A4SLC6A2
SCHEMBL6349980 0.77 CES2 (0.45) CES2CES1BRD4HDAC4HDAC7
SCHEMBL8064901 0.77 TSHR (0.42) ALDH1A1CES2CES1BRD4HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440690-B2 Quinuclidine carbonate salts and medicinal composition thereof CHIESI FARMACEUTICI S.P.A. (IT) 2013-05-14 US disclosed
US-8404712-B2 Quinuclidine carbonate salts and medicinal composition thereof CHIESI FARMACEUTICI S.P.A. (IT) 2013-03-26 US disclosed
EP-2313404-B1 QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHIESI FARMA SPA (IT) 2012-03-28 EP disclosed
US-20120004258-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2012-01-05 US disclosed
US-20110319444-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2011-12-29 US disclosed
US-8039483-B2 Quinuclidine carbonate salts and medicinal composition thereof CHIESI FARMACEUTICI S.P.A. (IT) 2011-10-18 US disclosed
EP-2313404-A1 QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.p.A. (IT) 2011-04-27 EP disclosed
WO-2010015324-A1 QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2010-02-11 WO disclosed
US-20100035922-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035922-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHRM3, CHRM2, CHRM4 ALDH1A1 2885/4885ESR1 1132/4885CES2 2730/4885
US-20120004258-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHRM3, CHRM2, CHRM4 ALDH1A1 2885/4885ESR1 1132/4885CES2 2730/4885
US-20110319444-A1 QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF CHRM3, CHRM2, CHRM4 ALDH1A1 2885/4885ESR1 1132/4885CES2 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.